Ardelyx, Inc. (NASDAQ: ARDX) is a Healthcare company (Biotechnology) with a market capitalization of $799M. The Maz Rating grades it against the other companies in its sector.
Ardelyx, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $3.18, Ardelyx, Inc. trades at 1.7x sales and 4.8x book value. Over the last twelve months it generated about $471M of revenue and a net loss of $57M. It runs a gross margin of 94.3%, an operating margin of -7.7% and a net margin of -11.8%. It shows return on equity of -35.3%, return on invested capital of -7.8% and a free cash flow yield of -2.0%. On the balance sheet: a debt-to-equity ratio of 1.56 and a current ratio of 3.45. Over the past 52 weeks the share price ranged from $2.80 to $8.40, with a beta of 0.68.
Ardelyx, Inc. does not currently pay a dividend.
16 Wall Street analyst ratings cover the stock: 16 Buy, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.